PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 5712人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期, objectType=article, longId=153166, objectId=251515316657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=251515316657, replyNumber=0, likeNumber=68, createdTime=2018-11-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=251515316657, moduleTitle=BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=251515316657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254974, encodeId=dc7112549e489, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著, objectType=article, longId=152644, objectId=1a4c15264424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a4c15264424, replyNumber=0, likeNumber=54, createdTime=2018-11-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a4c15264424, moduleTitle=NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a4c15264424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254973, encodeId=b83612549e3fc, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=一滴血就能预测PD-1/PD-L1免疫治疗效果，是真的吗？, objectType=article, longId=152270, objectId=cdcc1522e05b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdcc1522e05b, replyNumber=0, likeNumber=51, createdTime=2018-10-31, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdcc1522e05b, moduleTitle=一滴血就能预测PD-1/PD-L1免疫治疗效果，是真的吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdcc1522e05b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254972, encodeId=675612549e287, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=全球第6款PD-1/PD-L1肿瘤免疫疗法获批上市，竞争趋白热化！, objectType=article, longId=150497, objectId=844b15049ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=844b15049ed6, replyNumber=0, likeNumber=66, createdTime=2018-10-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=844b15049ed6, moduleTitle=全球第6款PD-1/PD-L1肿瘤免疫疗法获批上市，竞争趋白热化！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=844b15049ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254971, encodeId=4fd712549e188, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达, objectType=article, longId=150102, objectId=1ff11501029e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff11501029e, replyNumber=0, likeNumber=80, createdTime=2018-10-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff11501029e, moduleTitle=CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff11501029e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254970, encodeId=171d12549e06d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限, objectType=article, longId=149879, objectId=d9c41498e99b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c41498e99b, replyNumber=0, likeNumber=62, createdTime=2018-09-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c41498e99b, moduleTitle=马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c41498e99b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254969, encodeId=73be12549693c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, objectType=article, longId=149623, objectId=297e149623e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297e149623e6, replyNumber=0, likeNumber=62, createdTime=2018-09-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297e149623e6, moduleTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297e149623e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254968, encodeId=655b1254968f6, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号, objectType=article, longId=148786, objectId=bee6148e86b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee6148e86b0, replyNumber=0, likeNumber=110, createdTime=2018-09-15, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee6148e86b0, moduleTitle=Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee6148e86b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254967, encodeId=bf8d125496e7e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效, objectType=article, longId=148592, objectId=7d6414859221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6414859221, replyNumber=0, likeNumber=58, createdTime=2018-09-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6414859221, moduleTitle=BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6414859221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254966, encodeId=28ae125496625, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：基线类固醇对非小细胞肺癌患者PD-1/PD-L1阻断治疗有效性的影响, objectType=article, longId=147190, objectId=3dc814e1907e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc814e1907e, replyNumber=0, likeNumber=63, createdTime=2018-08-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc814e1907e, moduleTitle=JCO：基线类固醇对非小细胞肺癌患者PD-1/PD-L1阻断治疗有效性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc814e1907e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254965, encodeId=3b001254965b4, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Mol Cell:华人科学家首次发现二甲双胍可降解PD-L1，解除癌细胞对免疫细胞的压制，提高抗癌能力, objectType=article, longId=146968, objectId=288314696892, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=288314696892, replyNumber=0, likeNumber=66, createdTime=2018-08-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=288314696892, moduleTitle=Mol Cell:华人科学家首次发现二甲双胍可降解PD-L1，解除癌细胞对免疫细胞的压制，提高抗癌能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=288314696892)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254964, encodeId=7bad1254964f5, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=NATURE：外泌体PD-L1助力免疫抑制, objectType=article, longId=146378, objectId=1f661463e8fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f661463e8fa, replyNumber=0, likeNumber=62, createdTime=2018-08-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f661463e8fa, moduleTitle=NATURE：外泌体PD-L1助力免疫抑制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f661463e8fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254963, encodeId=3d0e12549638d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Chest：EBUS-TBNA与切除肺癌标本之间PD-L1免疫组化染色的比较, objectType=article, longId=145644, objectId=2f25145644a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f25145644a6, replyNumber=0, likeNumber=57, createdTime=2018-08-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f25145644a6, moduleTitle=Chest：EBUS-TBNA与切除肺癌标本之间PD-L1免疫组化染色的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f25145644a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254962, encodeId=2cd01254962d3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！, objectType=article, longId=145638, objectId=7bf3145638e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bf3145638e4, replyNumber=0, likeNumber=73, createdTime=2018-08-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bf3145638e4, moduleTitle=Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bf3145638e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254961, encodeId=9075125496183, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JAMA Oncol：PD-L1表达可以预测免疫治疗疗效，PD-L1基因扩增呢？, objectType=article, longId=141402, objectId=21e01414028f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e01414028f, replyNumber=0, likeNumber=0, createdTime=2018-06-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e01414028f, moduleTitle=JAMA Oncol：PD-L1表达可以预测免疫治疗疗效，PD-L1基因扩增呢？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e01414028f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254960, encodeId=2d04125496055, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Immunol：PD-1/PD-L1不响应机制被揭密，NK细胞其核心作用, objectType=article, longId=141325, objectId=cafd141325f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cafd141325f8, replyNumber=0, likeNumber=68, createdTime=2018-06-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cafd141325f8, moduleTitle=Nat Immunol：PD-1/PD-L1不响应机制被揭密，NK细胞其核心作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cafd141325f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254959, encodeId=e696125495944, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO速递：PD-L1表达可预测膀胱癌免疫治疗疗效, objectType=article, longId=139899, objectId=92ae13989904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ae13989904, replyNumber=0, likeNumber=113, createdTime=2018-06-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ae13989904, moduleTitle=ASCO速递：PD-L1表达可预测膀胱癌免疫治疗疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92ae13989904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254958, encodeId=a3be1254958e6, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性, objectType=article, longId=138186, objectId=481213818605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=481213818605, replyNumber=0, likeNumber=109, createdTime=2018-05-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=481213818605, moduleTitle=Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=481213818605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254957, encodeId=6507125495e04, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益, objectType=article, longId=136414, objectId=1d661364149a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d661364149a, replyNumber=0, likeNumber=50, createdTime=2018-04-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d661364149a, moduleTitle=PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d661364149a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254956, encodeId=326f125495686, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关, objectType=article, longId=134603, objectId=74e21346033e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74e21346033e, replyNumber=0, likeNumber=90, createdTime=2018-04-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74e21346033e, moduleTitle=Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74e21346033e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期

2018-11-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著

2018-11-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

一滴血就能预测PD-1/PD-L1免疫治疗效果，是真的吗？

2018-10-31

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

全球第6款PD-1/PD-L1肿瘤免疫疗法获批上市，竞争趋白热化！

2018-10-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达

2018-10-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限

2018-09-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌

2018-09-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号

2018-09-15

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效

2018-09-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：基线类固醇对非小细胞肺癌患者PD-1/PD-L1阻断治疗有效性的影响

2018-08-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Mol Cell:华人科学家首次发现二甲双胍可降解PD-L1，解除癌细胞对免疫细胞的压制，提高抗癌能力

2018-08-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

NATURE：外泌体PD-L1助力免疫抑制

2018-08-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Chest：EBUS-TBNA与切除肺癌标本之间PD-L1免疫组化染色的比较

2018-08-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！

2018-08-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JAMA Oncol：PD-L1表达可以预测免疫治疗疗效，PD-L1基因扩增呢？

2018-06-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Immunol：PD-1/PD-L1不响应机制被揭密，NK细胞其核心作用

2018-06-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ASCO速递：PD-L1表达可预测膀胱癌免疫治疗疗效

2018-06-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性

2018-05-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益

2018-04-26

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关

2018-04-10

科室
- - 订阅+
  - 更多科室
工具
服务